Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onkaido Therapeutics Inc.

Messenger RNA therapeutics for oncology

This article was originally published in Start Up

Executive Summary

Moderna Therapeutics says it has found ways to design, manufacture, formulate, and deliver mRNA so that it can instruct cells in different tissues and organs to make virtually any protein, intracellular or secreted. To begin commercializing drugs designed to make therapeutic proteins inside patients' own cells, Moderna has spun out Onkaido Therapeutics Inc. and funded it with $20 million and 15 oncology drug candidates, in the areas of apoptosis, central regulatory nodes, and immunotherapy.

Advertisement

Related Content

Start-Up Quarterly Statistics, Q1 2014
Biopharma Dealmaking Quarterly Statistics, Q1 2014
Strategic Spin-Outs: Biotechs Structure Their Progeny For Success

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel